Patient Support Programs (PSP) are gaining ground in Spain with a pioneering program by Logista Pharma.
10 March, 2026
- Coordinated with laboratories and hospitals, the company has launched a program for administering medications at patients’ homes.
- These models help improve treatment adherence and strengthen care continuity, especially in the first months of therapy.
- Logista Pharma highlights the importance of implementing these services with the highest guarantees of quality, patient safety, and data privacy.
Lack of adherence to treatment is a major healthcare challenge: various studies estimate that up to 50% of patients do not take their medication as prescribed, which may result in poorer clinical outcomes and increased use of healthcare resources. In this context, home-care models—always under the prescription and coordination of the clinical team—are becoming a key tool to reinforce continuity of care and help patients maintain their treatments, especially during the beginning of therapy. In fact, more than 85% of healthcare professionals state that the existence of these models influences prescribing decisions.
To address this challenge, Logista Pharma, the leading distributor of pharmaceutical products in Spain, has launched a pioneering Patient Support Program that includes, among other services, in-home administration and care provided by healthcare professionals, always in coordination with the hospital and its medical team.
“With the Patient Support Program, we aim to help prescriptions turn into real and sustained treatment, especially at critical times such as the beginning and first months, when the risk of discontinuation or incorrect use is highest,” says Ignacio Sánchez Caballero, General Manager Logista Pharma Iberia. He adds, “the goal is to support the patient while also helping optimize hospital resources—time, healthcare staff, and care capacity—without compromising the highest safety standards.”
Essential conditions: quality, patient safety, and privacy
Logista Pharma emphasizes that these services must be provided using operational procedures previously defined with all parties involved in the process, end-to-end traceability, quality controls, and regulatory compliance regarding data protection and patient safety. “Patient support only generates trust if it is based on a solid framework of quality, clinical safety, and data protection,” stresses Ignacio Sánchez Caballero.
In practice, the Patient Support Program operates in close coordination with the hospital: the center identifies and enrolls patients who meet the criteria; operational coordination and the action protocol are defined; care is delivered in the patient’s home by the nursing team; and follow-up is conducted, with service monitoring and reporting to the clinician as agreed, ensuring privacy and safety at all times.
“Beyond the care component, these programs provide clear social value: they help patients follow their treatments with fewer access barriers and more support, and contribute to greater sustainability of the healthcare system,” concludes the General Manager Logista Pharma Iberia.
Nationwide coverage: reaching patients wherever they are
One of the key advantages of these services is their ability to reach patients regardless of location. Logista Pharma’s program stands out for its potential to provide care in any municipality, regardless of population density, as long as the hospital considers the patient eligible. This approach helps reduce access barriers—mobility, distance to healthcare centers, or complex social-health circumstances—and avoid unnecessary travel, with direct impact on care continuity.
This progress aligns with structural changes in the healthcare system, with the growth of home care and the increase in outpatient hospital patients. In this context, these models can contribute to more efficient resource use and facilitate pathways linked to clinical trials and access to innovative therapies.
Although these mechanisms are still developing in Spain, international trends show steady growth, as seen in countries such as the United Kingdom, the United States, Canada, or New Zealand, where these models are more established. National expansion is expected to grow significantly in the coming years. However, these are medium- and long-term initiatives, often linked to clinical trials and the progressive incorporation of new therapies.
About Logista Pharma: logistapharma.com
Logista Pharma is the Logista company specialized in pharmaceutical distribution across all pharmaceutical channels in Spain, Portugal, and Italy. It offers the broadest range of services to meet the needs of the pharmaceutical industry. With a high-precision logistics network and services adapted to the healthcare sector, it guarantees traceability, safety, and regulatory compliance in the distribution of all products. Logista Pharma currently works with more than 250 client laboratories.
Logista Pharma relies on the group’s transport companies to deliver orders, ensuring full operational integration, real-time physical and thermal traceability, high quality standards, and the use of advanced information systems.
About Logista - logista.com
Logista is one of the largest logistics operators in Europe and specializes in distribution to proximity channels. It regularly serves around 200,000 points of sale in Spain, France, Italy, Portugal, the Netherlands, Belgium, and Poland, providing the best and fastest access to the market for a wide range of convenience, pharmaceutical, electronic recharge, books, publications, tobacco, and lottery products, among others. It also stands out as the largest transport network in Spain certified in food safety. Logista has a team of around 8,000 direct employees and a large number of collaborators.